Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Colorectal Neoplasms

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 71 articles:
HTML format
Text format



Single Articles


    February 2017
  1. JONES RP, Sutton PA, Evans JP, Clifford R, et al
    Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  2. LECLERC D, Pham DN, Levesque N, Truongcao M, et al
    Oncogenic role of PDK4 in human colon cancer cells.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  3. CARTER JV, Galbraith NJ, Yang D, Burton JF, et al
    Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis.
    Br J Cancer. 2017 Feb 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2017
  4. HU H, Shu M, He L, Yu X, et al
    Epigenomic landscape of 5-hydroxymethylcytosine reveals its transcriptional regulation of lncRNAs in colorectal cancer.
    Br J Cancer. 2017 Jan 31. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  5. MARMORINO F, Salvatore L, Barbara C, Allegrini G, et al
    Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
    Br J Cancer. 2017;116:318-323.
    PubMed     Text format     Abstract available


  6. AQUINA CT, Mohile SG, Tejani MA, Becerra AZ, et al
    The impact of age on complications, survival, and cause of death following colon cancer surgery.
    Br J Cancer. 2017 Jan 5. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    December 2016
  7. CRISTOBAL I, Torrejon B, Madoz-Gurpide J, Rojo F, et al
    Comment on 'MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells'.
    Br J Cancer. 2016 Dec 20. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  8. CHANDRASEKARAN KS, Sathyanarayanan A, Karunagaran D
    Reply: Comment on 'MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells'.
    Br J Cancer. 2016 Dec 20. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  9. VAN DER VLUGT M, Grobbee EJ, Bossuyt PM, Bongers E, et al
    Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening.
    Br J Cancer. 2016 Dec 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    November 2016
  10. RENNERT G
    Reproductive factors, hormones and colorectal cancer-still unresolved.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  11. MURPHY N, Xu L, Zervoudakis A, Xue X, et al
    Reproductive and menstrual factors and colorectal cancer incidence in the Women's Health Initiative Observational Study.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  12. DE SMEDT L, Palmans S, Andel D, Govaere O, et al
    Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching.
    Br J Cancer. 2016 Nov 24. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  13. DEN UIL SH, Coupe VM, Linnekamp JF, van den Broek E, et al
    Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.
    Br J Cancer. 2016 Nov 17. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  14. HE GY, Hu JL, Zhou L, Zhu XH, et al
    The FOXD3/miR-214/MED19 axis suppresses tumour growth and metastasis in human colorectal cancer.
    Br J Cancer. 2016 Nov 3. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  15. JIA M, Jansen L, Walter V, Tagscherer K, et al
    No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.
    Br J Cancer. 2016 Nov 3. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    October 2016
  16. MOSKAL A, Freisling H, Byrnes G, Assi N, et al
    Main nutrient patterns and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition study.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  17. KARTHAUS M, Hofheinz RD, Mineur L, Letocha H, et al
    Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  18. KIM TW, Elme A, Kusic Z, Park JO, et al
    A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.
    Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    September 2016
  19. MARZI L, Combes E, Vie N, Ayrolles-Torro A, et al
    FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.
    Br J Cancer. 2016 Sep 29. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  20. ROGERS AC, Winter DC, Heeney A, Gibbons D, et al
    Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer.
    Br J Cancer. 2016 Sep 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    August 2016
  21. FARSHIDFAR F, Weljie AM, Kopciuk KA, Hilsden R, et al
    A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
    Br J Cancer. 2016 Aug 25. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  22. RENZI C, Lyratzopoulos G, Card T, Chu TP, et al
    Do colorectal cancer patients diagnosed as an emergency differ from non-emergency patients in their consultation patterns and symptoms? A longitudinal data-linkage study in England.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  23. CHANDRASEKARAN KS, Sathyanarayanan A, Karunagaran D
    MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  24. ROSATO V, Guercio V, Bosetti C, Negri E, et al
    Mediterranean diet and colorectal cancer risk: a pooled analysis of three Italian case-control studies.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  25. LIGI D, Mannello F
    Do matrix metalloproteinases represent reliable circulating biomarkers in colorectal cancer?
    Br J Cancer. 2016 Aug 16. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  26. BEALE G, Haagensen EJ, Thomas HD, Wang LZ, et al
    Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.
    Br J Cancer. 2016 Aug 16. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  27. WALTER FM, Emery JD, Mendonca S, Hall N, et al
    Symptoms and patient factors associated with longer time to diagnosis for colorectal cancer: results from a prospective cohort study.
    Br J Cancer. 2016 Aug 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    July 2016
  28. DREWES JL, Housseau F, Sears CL
    Sporadic colorectal cancer: microbial contributors to disease prevention, development and therapy.
    Br J Cancer. 2016 Jul 5. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    June 2016
  29. JARVIS D, Mitchell JS, Law PJ, Palin K, et al
    Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  30. PILERI P, Campagnoli S, Grandi A, Parri M, et al
    FAT1: a potential target for monoclonal antibody therapy in colon cancer.
    Br J Cancer. 2016 Jun 21. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  31. CHA Y, Kim KJ, Han SW, Rhee YY, et al
    Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.
    Br J Cancer. 2016 Jun 16. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  32. VAN WYK HC, Park JH, Edwards J, Horgan PG, et al
    The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer.
    Br J Cancer. 2016 Jun 14. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  33. KONDO T, Okabayashi K, Hasegawa H, Tsuruta M, et al
    The impact of hepatic fibrosis on the incidence of liver metastasis from colorectal cancer.
    Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  34. LEE MS, McGuffey EJ, Morris JS, Manyam G, et al
    Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer.
    Br J Cancer. 2016 Jun 7. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    May 2016
  35. VAYRYNEN SA, Vayrynen JP, Klintrup K, Makela J, et al
    Clinical impact and network of determinants of tumour necrosis in colorectal cancer.
    Br J Cancer. 2016 May 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  36. KAPUR N, Mir H, Clark Iii CE, Krishnamurti U, et al
    CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition.
    Br J Cancer. 2016 May 5. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  37. OSAWA H, Takahashi H, Nishimura J, Ohta K, et al
    Full-length LGR5-positive cells have chemoresistant characteristics in colorectal cancer.
    Br J Cancer. 2016 May 3. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    April 2016
  38. PEREA J, Arriba M, Rueda D, Sanchez R, et al
    Comment on 'Wild-type APC prediction of poor prognosis in microsatellite-stable proximal colorectal cancer differs according to the age of onset'.
    Br J Cancer. 2016 Apr 26. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  39. JOHNSON SP, Ramasawmy R, Campbell-Washburn AE, Wells JA, et al
    Acute changes in liver tumour perfusion measured non-invasively with arterial spin labelling.
    Br J Cancer. 2016;114:897-904.
    PubMed     Text format     Abstract available


    March 2016
  40. BABIC A, Shah SM, Song M, Wu K, et al
    Soluble tumour necrosis factor receptor type II and survival in colorectal cancer.
    Br J Cancer. 2016 Mar 31. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  41. TAKAHASHI N, Iwasa S, Taniguchi H, Sasaki Y, et al
    Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies.
    Br J Cancer. 2016 Mar 22. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  42. WARSCHKOW R, Tarantino I, Huttner FJ, Schmied BM, et al
    Predictive value of mucinous histology in colon cancer: a population-based, propensity score matched analysis.
    Br J Cancer. 2016 Mar 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  43. POTTEGARD A, Ennis ZN, Hallas J, Jensen BL, et al
    Long-term use of lithium and risk of colorectal adenocarcinoma: a nationwide case-control study.
    Br J Cancer. 2016;114:571-5.
    PubMed     Text format     Abstract available


    February 2016
  44. ANNAHAZI A, Abraham S, Farkas K, Rosztoczy A, et al
    A pilot study on faecal MMP-9: a new noninvasive diagnostic marker of colorectal cancer.
    Br J Cancer. 2016 Feb 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  45. OHLSSON L, Hammarstrom ML, Lindmark G, Hammarstrom S, et al
    Ectopic expression of the chemokine CXCL17 in colon cancer cells.
    Br J Cancer. 2016 Feb 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  46. GRENADER T, Nash S, Adams R, Kaplan R, et al
    Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study.
    Br J Cancer. 2016 Feb 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  47. MAX N, Harbaum L, Pollheimer MJ, Lindtner RA, et al
    Tumour budding with and without admixed inflammation: two different sides of the same coin?
    Br J Cancer. 2016;114:368-71.
    PubMed     Text format     Abstract available


  48. KIRKOEN B, Berstad P, Botteri E, Avitsland TL, et al
    Do no harm: no psychological harm from colorectal cancer screening.
    Br J Cancer. 2016 Feb 11. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  49. LOMAKINA ME, Lallemand F, Vacher S, Molinie N, et al
    Arpin downregulation in breast cancer is associated with poor prognosis.
    Br J Cancer. 2016 Feb 11. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  50. PARK JH, Powell AG, Roxburgh CS, Horgan PG, et al
    Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment.
    Br J Cancer. 2016 Feb 9. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  51. MARSHALL DC, Webb TE, Hall RA, Salciccioli JD, et al
    Trends in UK regional cancer mortality 1991-2007.
    Br J Cancer. 2016;114:340-7.
    PubMed     Text format     Abstract available


  52. KEARNS B, Whyte S, Seaman HE, Snowball J, et al
    Factors associated with completion of bowel cancer screening and the potential effects of simplifying the screening test algorithm.
    Br J Cancer. 2016;114:327-33.
    PubMed     Text format     Abstract available


  53. RAINE R, Duffy SW, Wardle J, Solmi F, et al
    Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening.
    Br J Cancer. 2016;114:321-6.
    PubMed     Text format     Abstract available


    January 2016
  54. KIM SA, Inamura K, Yamauchi M, Nishihara R, et al
    Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis.
    Br J Cancer. 2016;114:199-206.
    PubMed     Text format     Abstract available


  55. GILBERT DC, Serup-Hansen E, Linnemann D, Hogdall E, et al
    Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer.
    Br J Cancer. 2016;114:134-7.
    PubMed     Text format     Abstract available


  56. GARCIA-ALBENIZ X, Rudolph A, Hutter C, White E, et al
    CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk.
    Br J Cancer. 2016 Jan 14. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  57. ELEZ E, Hendlisz A, Delaunoit T, Sastre J, et al
    Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.
    Br J Cancer. 2016 Jan 14. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  58. KEUM N, Cao Y, Lee DH, Park SM, et al
    Male pattern baldness and risk of colorectal neoplasia.
    Br J Cancer. 2016;114:110-7.
    PubMed     Text format     Abstract available


    December 2015
  59. O'DONNELL C, Mahmoud A, Keane J, Murphy C, et al
    An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer.
    Br J Cancer. 2015 Dec 17. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  60. DANIEL CR, Shu X, Ye Y, Gu J, et al
    Severe obesity prior to diagnosis limits survival in colorectal cancer patients evaluated at a large cancer centre.
    Br J Cancer. 2015 Dec 17. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  61. AMATU A, Somaschini A, Cerea G, Bosotti R, et al
    Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.
    Br J Cancer. 2015 Dec 3. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  62. AHERN TP, Horvath-Puho E, Spindler KG, Sorensen HT, et al
    Colorectal cancer, comorbidity, and risk of venous thromboembolism: assessment of biological interactions in a Danish nationwide cohort.
    Br J Cancer. 2015 Dec 1. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  63. RENAUD S, Falcoz PE, Romain B, Olland A, et al
    Reply: Comment on 'KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colo-rectal cancer'.
    Br J Cancer. 2015;113:1637-8.
    PubMed     Text format    


  64. ROWLAND A, Dias MM, Wiese MD, Kichenadasse G, et al
    Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'.
    Br J Cancer. 2015;113:1635.
    PubMed     Text format    


    November 2015
  65. LOUPAKIS F, Moretto R, Aprile G, Muntoni M, et al
    Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.
    Br J Cancer. 2015 Nov 17. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


  66. NADARZYNSKI T, Smith HE, Richardson D, Ford E, et al
    Sexual healthcare professionals' views on HPV vaccination for men in the UK.
    Br J Cancer. 2015 Nov 17. doi: 10.1038/bjc.2015.
    PubMed     Text format     Abstract available


    October 2015
  67. RESTIVO A, Cocco IM, Casula G, Scintu F, et al
    Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer.
    Br J Cancer. 2015;113:1133-9.
    PubMed     Text format     Abstract available


    September 2015
  68. KHELWATTY SA, Essapen S, Seddon AM, Fan Z, et al
    Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.
    Br J Cancer. 2015;113:1010-9.
    PubMed     Text format     Abstract available


  69. EXNER R, Pulverer W, Diem M, Spaller L, et al
    Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkers.
    Br J Cancer. 2015;113:1035-45.
    PubMed     Text format     Abstract available


  70. SARIDAKI Z, Saegart X, De Vriendt V, Hatzidaki D, et al
    KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?
    Br J Cancer. 2015;113:914-20.
    PubMed     Text format     Abstract available


  71. HASHIBE M, Galeone C, Buys SS, Gren L, et al
    Coffee, tea, caffeine intake, and the risk of cancer in the PLCO cohort.
    Br J Cancer. 2015;113:809-16.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: